Keeping it cool has become the logistics industry's hottest business. The GLP-1 boom is driving billions into cold-chain infrastructure, turning healthcare into one of shipping's fastest-growing and most lucrative segments.
Racing to refrigerate: The GLP-1 boom has turned temperature control into a competitive advantage. A July Gallup poll found that 11% of Americans now take GLP-1 medications for weight loss, up from just 3% in 2024. Injectable drugs like Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound have to stay refrigerated throughout shipping. Even a short temperature swing can affect the medicine, giving logistics companies little room for error.
FedEx is doubling down on healthcare with the launch of FedEx Life Sciences, a business dedicated to pharmaceutical customers. Healthcare transportation generated nearly $10B in revenue during fiscal 2026, making it one of FedEx's fastest-growing businesses. Rival UPS has already committed $48M to cold-chain facilities and spent $1.6B to acquire Andlauer Healthcare Group.
The margin equation: Supply Chain Insights founder Lora Cecere says healthcare is one of logistics' most profitable markets because pharmaceuticals carry some of manufacturing's highest margins. A failed cold-chain shipment can mean ruined medicine, regulatory penalties, and wasted product. In this business, certainty is cheaper than failure.
Chipflation Has Wall Street Hunting for the Next Hardware Winners
Fast Food’s Value War Enters a New Phase as Discounts Lose Power
